INCY
Price
$113.25
Change
+$0.18 (+0.16%)
Updated
Oct 19 closing price
Capitalization
22.96B
9 days until earnings call
Intraday BUY SELL Signals
REGN
Price
$782.04
Change
-$8.70 (-1.10%)
Updated
Oct 19 closing price
Capitalization
80.51B
10 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

INCY vs REGN

INCY vs REGN Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
INCY vs. REGN commentary
Oct 20, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INCY is a Hold and REGN is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for INCY with price predictions
Oct 19, 2026

INCY in +4.28% Uptrend, rising for three consecutive days on October 15, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where INCY advanced for three days, in 210 of 328 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where INCY's RSI Oscillator exited the oversold zone, 18 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 53%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 37 of 60 cases where INCY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 62%.

INCY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INCY as a result. In 47 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 49%.

INCY moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for INCY crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INCY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.

The Aroon Indicator for INCY entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 44 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is 51 (best 1 - 100 worst), indicating fairly steady price growth. INCY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 78 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.618) is normal, around the industry mean (2.978). P/E Ratio (13.930) is within average values for comparable stocks, (-0.692). Projected Growth (PEG Ratio) (10.822) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (134.267) among similar stocks. P/S Ratio (4.401) is also within normal values, averaging (438.009).

A.I.Advisor
a Summary for REGN with price predictions
Oct 19, 2026

REGN's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for REGN turned positive on October 14, 2026. Looking at past instances where REGN's MACD turned positive, the stock continued to rise in 33 of 49 cases over the following month. The odds of a continued upward trend are 67%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where REGN's RSI Indicator exited the oversold zone, 18 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.

The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on REGN as a result. In 57 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 61%.

Following a +5.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where REGN advanced for three days, in 207 of 318 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

REGN moved below its 50-day moving average on October 19, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for REGN crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 50%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where REGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.

REGN broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for REGN entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. REGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 86 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.539) is normal, around the industry mean (2.978). P/E Ratio (18.678) is within average values for comparable stocks, (-0.692). Projected Growth (PEG Ratio) (1.238) is also within normal values, averaging (9.059). Dividend Yield (0.005) settles around the average of (134.267) among similar stocks. P/S Ratio (5.339) is also within normal values, averaging (438.009).

FUNDAMENTALS RATINGS
INCY vs REGN: Fundamental Ratings
INCY
REGN
OUTLOOK RATING
1..100
5711
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
88
Overvalued
PROFIT vs RISK RATING
1..100
4486
SMR RATING
1..100
3359
PRICE GROWTH RATING
1..100
5150
P/E GROWTH RATING
1..100
7816
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REGN's Valuation (88) in the Biotechnology industry is in the same range as INCY (92). This means that REGN’s stock grew similarly to INCY’s over the last 12 months.

INCY's Profit vs Risk Rating (44) in the Biotechnology industry is somewhat better than the same rating for REGN (86). This means that INCY’s stock grew somewhat faster than REGN’s over the last 12 months.

INCY's SMR Rating (33) in the Biotechnology industry is in the same range as REGN (59). This means that INCY’s stock grew similarly to REGN’s over the last 12 months.

REGN's Price Growth Rating (50) in the Biotechnology industry is in the same range as INCY (51). This means that REGN’s stock grew similarly to INCY’s over the last 12 months.

REGN's P/E Growth Rating (16) in the Biotechnology industry is somewhat better than the same rating for INCY (78). This means that REGN’s stock grew somewhat faster than INCY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INCYREGN
RSI
ODDS (%)
Bullish Trend 1 day ago
53%
Bullish Trend 1 day ago
67%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
62%
Bearish Trend 1 day ago
61%
Momentum
ODDS (%)
Bearish Trend 1 day ago
49%
Bullish Trend 1 day ago
61%
MACD
ODDS (%)
N/A
Bullish Trend 1 day ago
67%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
65%
Bullish Trend 1 day ago
64%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
57%
Bearish Trend 1 day ago
62%
Advances
ODDS (%)
Bullish Trend 5 days ago
64%
Bullish Trend 5 days ago
65%
Declines
ODDS (%)
Bearish Trend 7 days ago
55%
Bearish Trend 1 day ago
56%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
55%
Bearish Trend 1 day ago
60%
Aroon
ODDS (%)
Bearish Trend 1 day ago
57%
Bearish Trend 1 day ago
68%
COMPARISON
Comparison
Oct 20, 2026
Stock price -- (INCY: $113.25 vs. REGN: $782.04)
Brand notoriety: INCY and REGN are both notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INCY: 71% vs. REGN: 65%
Market capitalization -- INCY: $22.96B vs. REGN: $80.51B
INCY [@Biotechnology] is valued at $22.96B. REGN’s [@Biotechnology] market capitalization is $80.51B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $127.22B. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INCY’s FA Score shows that 1 FA rating(s) are green while REGN’s FA Score has 1 green FA rating(s).

  • INCY’s FA Score: 1 green, 4 red.
  • REGN’s FA Score: 1 green, 4 red.
According to our system of comparison, both INCY and REGN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INCY’s TA Score shows that 4 TA indicator(s) are bullish while REGN’s TA Score has 4 bullish TA indicator(s).

  • INCY’s TA Score: 4 bullish, 5 bearish.
  • REGN’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, INCY is a better buy in the short-term than REGN.

Price Growth

INCY (@Biotechnology) experienced а +1.70% price change this week, while REGN (@Biotechnology) price change was +2.52% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.86%. For the same industry, the average monthly price growth was -18.66%, and the average quarterly price growth was -19.56%.

Reported Earning Dates

INCY is expected to report earnings on Oct 29, 2026.

REGN is expected to report earnings on Oct 30, 2026.

Industries' Descriptions

@Biotechnology (-7.86% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
INCY
Daily Signal:
Gain/Loss:
REGN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BHC6.320.02
+0.32%
Bausch Health Companies
JATT10.25-0.01
-0.05%
Jatt II Acquisition Corp
LII355.78-1.95
-0.55%
Lennox International
COFS32.84-0.26
-0.79%
ChoiceOne Financial Services
MBIO0.37N/A
-0.90%
Mustang Bio Inc

INCY and

Correlation & Price change

A.I.dvisor indicates that over the last year, INCY has been loosely correlated with RPRX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if INCY jumps, then RPRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INCY
1D Price
Change %
INCY100%
+0.16%
RPRX - INCY
46%
Loosely correlated
-1.13%
HALO - INCY
43%
Loosely correlated
+0.54%
VRTX - INCY
40%
Loosely correlated
+0.44%
AXON - INCY
39%
Loosely correlated
-1.84%
ACAD - INCY
37%
Loosely correlated
+3.56%
More

REGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, REGN has been loosely correlated with VRTX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then VRTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REGN
1D Price
Change %
REGN100%
-1.10%
VRTX - REGN
43%
Loosely correlated
+0.44%
RPRX - REGN
36%
Loosely correlated
-1.13%
BMRN - REGN
36%
Loosely correlated
-0.02%
ARQT - REGN
36%
Loosely correlated
+10.65%
INCY - REGN
33%
Loosely correlated
+0.16%
More